Serum thymidine kinase 1 levels predict cancer‑free survival following neoadjuvant, surgical and adjuvant treatment of patients with locally advanced breast cancer

  • Authors:
    • Feiyu Chen
    • Lili Tang
    • Ting Xia
    • Ellen He
    • Guozhu Hu
    • Yuan Li
    • Ming Zhang
    • Ji Zhou
    • Staffan Eriksson
    • Sven Skog
  • View Affiliations

  • Published online on: July 19, 2013     https://doi.org/10.3892/mco.2013.149
  • Pages: 894-902
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In this study, the use of serum thymidine kinase 1 protein (STK1p) concentration for the prognosis of the overall survival of patients with locally advanced breast cancer (n=51) following routine treatment (neoadjuvant treatment, surgery and chemotherapy) was investigated. The patients were followed up for 44 months and the STK1p values were determined by a high‑sensitivity enhanced chemiluminescence (ECL) dot blot assay. The variables investigated in relation to metastasis and survival were STK1p, clinical stage, tumor size and age, by the Kaplan‑Meier method, the log‑rank test and Cox uni‑ and multivariate analyses. Patients with high STK1p values (≥2.0 pM) 3‑6 months after surgery exhibited a positive correlation to clinical stage, tumor size, occurrence of metastasis and survival. The hazard risk for the development of metastatic disease and mortality among breast cancer patients was 11‑12 times higher in patients with high compared to those with low STK1p values (<2.0 pM). Notably, patients with stage III̸IV disease and low STK1p values exhibited statistically significantly improved survival compared to patients with high STK1p values. A multivariate Cox analysis demonstrated that the STK1p levels 6 months after surgery was the only independent prognostic factor for metastasis and survival. In conclusion, STK1p is a prognostic marker in patients with locally advanced breast cancer and it may help identify a subgroup of stage III̸IV patients with improved cancer‑free survival expectancy, enabling personalized treatment.
View Figures
View References

Related Articles

Journal Cover

September 2013
Volume 1 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Chen, F., Tang, L., Xia, T., He, E., Hu, G., Li, Y. ... Skog, S. (2013). Serum thymidine kinase 1 levels predict cancer‑free survival following neoadjuvant, surgical and adjuvant treatment of patients with locally advanced breast cancer. Molecular and Clinical Oncology, 1, 894-902. https://doi.org/10.3892/mco.2013.149
MLA
Chen, F., Tang, L., Xia, T., He, E., Hu, G., Li, Y., Zhang, M., Zhou, J., Eriksson, S., Skog, S."Serum thymidine kinase 1 levels predict cancer‑free survival following neoadjuvant, surgical and adjuvant treatment of patients with locally advanced breast cancer". Molecular and Clinical Oncology 1.5 (2013): 894-902.
Chicago
Chen, F., Tang, L., Xia, T., He, E., Hu, G., Li, Y., Zhang, M., Zhou, J., Eriksson, S., Skog, S."Serum thymidine kinase 1 levels predict cancer‑free survival following neoadjuvant, surgical and adjuvant treatment of patients with locally advanced breast cancer". Molecular and Clinical Oncology 1, no. 5 (2013): 894-902. https://doi.org/10.3892/mco.2013.149